ArticleInternational journal of obesity (2005)2025
Visual demonstration of weight loss and health risk improvement with a dual GIP and GLP-1 receptor agonist.
Article in International journal of obesity (2005), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundBody weight and health-outcome results of highly effective new GLP-1R agonist medicine trials are usually presented in scientific reports in the form of standard graphs and tables. These representations are not easily translated to what the average participant looked like or their health risks at the outset of the study and how improvements in adiposity and clinical measures changed with treatment. Two recently developed methods for visually presenting complex weight and health-risk information that encapsulate substantial amounts of clinical trial observations were recently developed that can potentially supplement and give new insights into conventional GLP-1R agonist scientific reports. The current study aim was to put these visual presentations into a demonstration format to explore if and to what extent they convey new or useful information beyond traditional graphical and tabular approaches.
methodsThe first developed approach was the capability of generating, with manifold regression, humanoid avatars with accurate anthropometric dimensions. The second developed approach, body roundness index (BRI), associates a person's shape phenotype with high-risk adiposity components and multiple health outcomes; BRI can be displayed in a visual format. These two approaches were applied to produce visual representations of body size and shape in Surmount 1 average male and female participants (maximal-tolerated dose group) at baseline and after 72-weeks of tirzepatide treatment.
resultsDeveloped images revealed clear excess adiposity and high health-risk (BRI) at baseline with marked improvements, although not to within the healthy BMI (<25 kg/m
conclusionsVisual presentation of new weight loss medicine trial results can supplement standard published reports by condensing substantial amounts of complex technical information in an easily understood format that can potentially yield new study insights.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.